CEA, AFP and CA 19-9 analysis in peritoneal fluid to differentiate causes of ascites formation

Clinical Biochemistry

Volumn 46, Issue 9, 2013, Pages 814-818

  Kaleta, Erin J ^a   Tolan, Nicole V ^a   Ness, Karl A ^a   O'Kane, Dennis ^a   Algeciras Schimnich, Alicia ^a  

^a MAYO CLINIC   (United States)

Author keywords

AFP; Ascites; CA 19 9; CEA; Tumor marker analysis

Indexed keywords

ALPHA FETOPROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ACCURACY; ARTICLE; ASCITES; BLADDER CANCER; BREAST CANCER; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; CYTOLOGY; DIGESTIVE SYSTEM CANCER; FEMALE; GYNECOLOGIC CANCER; HEMOLYSIS; HUMAN; HYPERLIPIDEMIA; IMMUNOASSAY; JAUNDICE; KIDNEY CANCER; LEIOMYOSARCOMA; LEUKEMIA; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT ASCITES; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MELANOMA; MESOTHELIOMA; NEUROENDOCRINE TUMOR; PANCREAS CANCER; PERITONEAL FLUID; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ALPHA-FETOPROTEINS; ASCITES; ASCITIC FLUID; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MALE; NEOPLASMS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84877921817     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.02.010     Document Type: Article

References (19)

1. Runyon B.A., Montano A.A., Akriviadis E.A., Antillon M.R., Irving M.A., McHutchison J.G. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992, 117:215-220.
2. Runyon B.A., Hoefs J.C., Morgan T.R. Ascitic fluid analysis in malignancy-related ascites. Hepatology 1988, 8:1104-1109.
3. Motherby H., Nadjari B., Friegel P., Kohaus J., Ramp U., Bocking A. Diagnostic accuracy of effusion cytology. Diagn Cytopathol 1999, 20:350-357.
4. Sari R., Yildirim B., Sevinc A., Bahceci F., Hilmioglu F. The importance of serum and ascites fluid alpha-fetoprotein, carcinoembryonic antigen, ca 19-9, and ca 15-3 levels in differential diagnosis of ascites etiology. Hepatogastroenterology 2001, 48:1616-1621.
5. Tuzun Y., Yilmaz S., Dursun M., Canoruc F., Celik Y., Cil T., et al. How to increase the diagnostic value of malignancy-related ascites: discriminative ability of the ascitic tumour markers. J Int Med Res 2009, 37:87-95.
6. Hackbarth J.S., Murata K., Reilly W.M., Algeciras-Schimnich A. Performance of CEA and CA 19-9 in identifying pleural effusions caused by specific malignancies. Clin Biochem 2010, 43:1051-1055.
7. Chevinsky A.H. CEA in tumors of other than colorectal origin. Semin Surg Oncol 1991, 7:162-166.
8. Ballesta A.M., Molina R., Filella X., Jo J., Gimenez N. Carcinoembryonic antigen in staging and follow-up of patients with solid tumors. Tumour Biol 1995, 16:32-41.
9. Goonetilleke K.S., Siriwardena A.K. Systematic review of carbohydrate antigen (ca 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007, 33:266-270.
10. Grem J. The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract. Curr Opin Oncol 1997, 9:380-387.
11. van der Bij S., Schaake E., Koffijberg H., Burgers J.A., de Mol B.A., Moons K.G. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer 2011, 104:1325-1333.
12. Cabibbo G., Craxi A. Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 2010, 14:352-355.
13. Clinical and Laboratory Standards Institute Evaluation of detection capability for clinical laboratory measurement procedures; approved guideline 2012, CLSI document EP17-A2, Clinical and Laboratory Standards Institute, Wayne, PA. 2nd ed.
14. Chen S.J., Wang S.S., Lu C.W., Chao Y., Lee F.Y., Lee S.D., et al. Clinical value of tumour markers and serum-ascites albumin gradient in the diagnosis of malignancy-related ascites. J Gastroenterol Hepatol 1994, 9:396-400.
15. Gerbes A.L., Jungst D., Xie Y.N., Permanetter W., Paumgartner G. Ascitic fluid analysis for the differentiation of malignancy-related and nonmalignant ascites. Proposal of a diagnostic sequence. Cancer 1991, 68:1808-1814.
16. Steinberg W. The clinical utility of the ca 19-9 tumor-associated antigen. Am J Gastroenterol 1990, 85:350-355.
17. Collier J., Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998, 27:273-278.
18. Macdonald J.S. Carcinoembryonic antigen screening: pros and cons. Semin Oncol 1999, 26:556-560.
19. Vestergaard E.M., Hein H.O., Meyer H., Grunnet N., Jorgensen J., Wolf H., et al. Reference values and biological variation for tumor marker ca 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and lewis genotyping in a Caucasian population. Clin Chem 1999, 45:54-61.